Valuation : Edesa Biotech, Inc.

Market Cap 64.31M 55.51M 52.28M 47.7M 89.04M 6.11B 89.74M 619M 240M 3.11B 241M 236M 10.21B P/E 2026 *
-2.4x
P/E 2027 * -2.3x
Enterprise Value 64.31M 55.51M 52.28M 47.7M 89.04M 6.11B 89.74M 619M 240M 3.11B 241M 236M 10.21B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
86.54%
Yield 2026 *
-
Yield 2027 * -
1 day-0.42%
1 week+6.97%
Current month+0.53%
1 month-6.85%
3 months-28.85%
6 months+116.36%
Current year+235.21%
1 week 4.45
Extreme 4.45
5.05
1 month 4.12
Extreme 4.12
6.67
Current year 0.72
Extreme 0.72
20.32
1 year 0.72
Extreme 0.72
20.32
3 years 0.72
Extreme 0.72
20.32
5 years 0.72
Extreme 0.72
84
10 years 0.72
Extreme 0.72
133.7
Manager TitleAgeSince
Chief Executive Officer 55 01/08/2015
Director of Finance/CFO 57 01/05/2025
President 48 07/06/2019
Director TitleAgeSince
Chairman 50 07/06/2019
Director/Board Member 55 07/06/2019
Chairman 70 -
Date Insider Type Main position Quantity % Market Cap. Importance
3/8/26 Free

Founder

5,324 0.0553%
2/7/26 Free

Founder

3,378 0.0380%
1/6/26 Free

Founder

1,671 0.0188%
Change 5-day change 1-year change 3-year change Capi.($)
-0.42%+6.97%+105.17%-18.76% 64.59M
+1.03%-3.11%+39.80%+94.60% 68.21B
+1.62%+2.43%+48.66%+88.33% 64.25B
+4.21%+2.21%-6.96%+459.32% 26.54B
+1.83%-8.98%+3.81%-14.74% 25.61B
+1.30%-0.96%+32.58%-17.99% 19.88B
-0.38%-12.42%+224.86%+373.18% 17.13B
+0.65%-5.83%+1.44%+544.44% 14.93B
+2.88%+3.19%+56.41%+157.39% 14.1B
+1.53%+6.79%+24.91%+195.41% 12.45B
Average +1.42%-2.63%+53.07%+186.12% 26.32B
Weighted average by Cap. +1.60%-3.01%+43.27%+162.46%

Financials

2026 *2027 *
Net sales - -
Net income -17.52M -15.12M -14.24M -13M -24.26M -1.66B -24.45M -169M -65.43M -847M -65.8M -64.37M -2.78B -29.25M -25.25M -23.78M -21.69M -40.5M -2.78B -40.81M -282M -109M -1.41B -110M -107M -4.65B
Net Debt - -
Logo Edesa Biotech, Inc.
Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company developing ways to treat inflammatory and immune-related diseases. The Company’s clinical pipeline is focused on two therapeutic areas: medical dermatology and respiratory. In medical dermatology, the Company is developing EB06, an anti-CXCL10 monoclonal antibody candidate, as a therapy for vitiligo, a common autoimmune disorder that causes skin to lose its color in patches. Its medical dermatology assets also include EB01 (1.0% daniluromer cream), a Phase III-ready asset developed for use as a potential therapy for moderate-to-severe chronic allergic contact dermatitis (ACD), a common occupational skin condition. The Company’s advanced respiratory drug candidate is EB05 (paridiprubart), which is being evaluated in a United States government-funded platform study as a treatment for acute respiratory distress syndrome.
Employees
-
Date Price Change Volume
02/09/26 USD 4.760 -0.42% 19,739
01/09/26 USD 4.780 +0.95% 24,179
31/08/26 USD 4.735 +2.49% 91,748
28/08/26 USD 4.620 +0.43% 70,656
27/08/26 USD 4.600 -6.88% 81,257
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
4.760USD
Average target price
16.33USD
Spread / Average Target
+243.14%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. EDSA Stock